

Sensorion announces R&D Day focusing on its Gene Therapy programs

Save the Date – Thursday April 6, 2023, at 8am EDT

Montpellier, February 21, 2023 – Sensorion, (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, invites you to attend its **R&D Day** on Thursday 6 April 2023, at 8 am EDT (2 pm CEST). The event will be held at the Hearing Institute (Institut de l’Audition), an Institut Pasteur center, located at 63, rue de Charenton, 75012, Paris, France. A live webcast and a replay of the presentation will also be accessible.

Sensorion’s management team, including CEO Nawal Ouzren, Géraldine Honnet, M.D., Chief Medical Officer, Laurent Desire, Ph.D., Head of Preclinical Development, and Christine Le Bec, Ph.D., Head of CMC Gene Therapy, will provide an update on the Company’s gene therapy programs, OTOF-GT and GJB2-GT, for the treatment of hereditary monogenic forms of deafness and expected milestones in 2023.

Key Opinion Leaders (KOLs) from the field of hearing therapeutics will also give presentations related to patient needs, therapeutics and market landscape and surgical approaches specific to hereditary monogenic forms of deafness key areas.

If you wish to attend the R&D Day in-person please contact us by email at ir@sensorion-pharma.com. The event will also be webcast live with registration details available in due course.

About Sensorion

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies.

Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

Sensorion pursues its broad strategic collaboration with the Institut Pasteur focused on the genetics of hearing. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including OTOF-GT, targeting deafness caused by mutations of the gene encoding for otoferlin, and hearing loss related to mutations in *GJB2* gene to potentially address important hearing loss segments in adults and children (GJB2-GT). The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

www.sensorion.com



Press release

Contacts

Investor Relations

Noemie Djokovic
Investor Relations and Communications
+33 6 76 67 98 31
ir.contact@sensorion-pharma.com

International Media Relations

Consilium Strategic Communications
Matthew Cole/Jessica Hodgson
+44 7593 572720
+44 7561 424788
Sensorion@consilium-comms.com

Label: **SENSORION**
ISIN: **FR0012596468**
Mnemonic: **ALSEN**



Disclaimer

This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2021 full year financial report published on April 28, 2022, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.